Compare Recursion Pharmaceuticals Inc (RXRX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while YieldMax Universe Fund of Option Income ETFs trades at $7.53. Which is the better fit depends on your goals.
| RXRX | YMAX | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $6.79 | $13.14 |
52-Week Low | $2.84 | $7.27 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
YMAX trades at $7.70 with a slight 0.13% daily gain, showing modest positive momentum. The technical outlook is bullish with moving averages supporting upward movement, though oscillators remain neutral. Recent news highlights the fund's weekly dividend distributions but also raises concerns about NAV erosion and sustainability of the high-yield strategy. The fund's structure as a fund-of-funds adds layers of costs that impact overall returns.
YMAX faces significant challenges with declining share price despite high distributions, suggesting the current yield may be unsustainable. The fund's principal erosion and structural cost issues present substantial risks for income-focused investors. While technical indicators show short-term bullish signals, fundamental concerns about the distribution policy and NAV performance warrant cautious consideration for long-term investment viability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
